Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12364132 | 0.97 | — | — | |
| SCHEMBL491156 | 0.92 | ACHE (0.32) | — | |
| SCHEMBL9944453 | 0.86 | — | — | |
| SCHEMBL1697213 | 0.80 | PDK1 (0.33) | CA1CA12CA7CA14 | |
| SCHEMBL10146064 | 0.80 | CA12 (0.31) | CA1CA12CA7CA14 | |
| SCHEMBL14227526 | 0.77 | — | — | |
| SCHEMBL14241860 | 0.77 | CYP1A2 (0.32) | — | |
| SCHEMBL14667211 | 0.75 | CNR2 (0.38) | — | |
| SCHEMBL10171127 | 0.75 | ADH1B (0.30) | — | |
| SCHEMBL7783201 | 0.75 | CA12 (0.31) | CA1CA12CA7CA14EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230057401-A1 | COATED UNDERLAYER FOR OVERCOATED PHOTORESIST | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2023-02-23 | — | — | US | disclosed |
| US-11236111-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-10894777-B2 | TG2 inhibitor piperazine compounds and uses thereof | UNIVERSITY OF OTTAWA (CA) | 2021-01-19 | — | — | US | disclosed |
| US-20200377519-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200317678-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10723733-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10640511-B2 | Hepatitis B antiviral agents | Enant Pharmaceuticals, Inc. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10428070-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170073334-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-16 | — | — | US | disclosed |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | EA PHARMA CO., LTD. (JP) | 2016-11-17 | — | — | US | disclosed |
| US-9365523-B2 | Imidazolyl amide compounds and uses related thereto | EMORY UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| US-9315454-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20140080828-A1 | IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO | CHILDREN'S HEATLHCARE OF ATLANTA, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2418207-A1 | Sulfone compounds which modulate the CB2 receptor | Boehringer Ingelheim International GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080828-A1 | IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO | TPMT, PNP, MTAP | CA1 3743/4885CA12 4026/4885CA7 1293/4885 |
| US-11236111-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | CA1 3742/4885CA12 2997/4885CA7 3147/4885 |
| US-20160332999-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME | TRPA1, TRPV1, TRPV2 | CA1 1394/4885CA12 2393/4885CA7 2046/4885 |
| US-20170073334-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | CA1 4866/4885CA12 4801/4885CA7 4612/4885 |
| US-20200317678-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | CA1 3742/4885CA12 2997/4885CA7 3147/4885 |
| US-20190177320-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | CA1 3742/4885CA12 2997/4885CA7 3147/4885 |
| US-10428070-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | CA1 3742/4885CA12 2997/4885CA7 3147/4885 |
| US-20200377519-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | CA1 3742/4885CA12 2997/4885CA7 3147/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | CA1 2728/4885CA12 1636/4885CA7 4558/4885 |
| US-20170355701-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, SLC10A1, HDGF | CA1 3742/4885CA12 2997/4885CA7 3147/4885 |
| US-10723733-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | CA1 3742/4885CA12 2997/4885CA7 3147/4885 |
| US-10894777-B2 | TG2 inhibitor piperazine compounds and uses thereof | TGM2, TGM1, TGM3 | CA1 854/4885CA12 2544/4885CA7 2139/4885 |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | CA1 2728/4885CA12 1636/4885CA7 4558/4885 |
| US-10640511-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | CA1 3742/4885CA12 2997/4885CA7 3147/4885 |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | CA1 2728/4885CA12 1636/4885CA7 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.